Quest Diagnostics Incorporated (DGX)

Check out top investors' recommendation for DGX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
120.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company operates in two businesses, Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business offers clinical testing services, including routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights. The Diagnostic Solutions business provides risk assessment services for the life insurance industry; clinical testing services for new drugs, vaccines, and medical devices; and clinical connectivity and data management solutions for healthcare organizations and clinicians to improve patient care and medical practice, as well as develops, manufactures, and markets diagnostics products. Its products include HemoCue, a point-of-care testing product for hemoglobin, glucose, microalbumin, and white blood cell testing; Care360 HER that allows doctors to electronically create, manage, and distribute patient encounter notes; and ChartMaxx, an electronic document management system for hospitals. The company offers its services to patients, physicians, hospitals, integrated delivery networks, health plans, employers, governmental institutions, and other commercial clinical laboratories through a network of laboratories and patient service centers. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Amanda Murphy William Blair & Company, L.L.C. Buy   Jun 08, '18       Jun 08, '19  N/A 
Ricky Goldwasser Morgan Stanley Buy   May 29, '18     120.00  May 29, '19  N/A 
Ann Hynes Mizuho Securities USA Buy   May 25, '18       May 25, '19  N/A 
Ann Hynes Mizuho Securities USA Buy   Oct 19, '17     103.00  Oct 19, '18  N/A 
Nicholas Jansen Raymond James Buy   Jun 26, '17       Jun 26, '18  N/A 
Jeffrey Frelick Canaccord Genuity Buy   Apr 25, '17     115.00  Apr 25, '18  N/A 
Ann Hynes Mizuho Securities USA Buy   Apr 14, '17     110.00  Apr 14, '18  N/A 
Dan Leonard Leerink Swann Llc Buy   Jan 18, '17     108.00  Jan 18, '18  N/A 
Ann Hynes Mizuho Securities USA Buy   Mar 01, '16   67.12  75.00  Mar 01, '17  45.17% 
Jeffrey Frelick Canaccord Genuity Buy   Aug 03, '15   72.57  82.00  Aug 03, '16  17.46% 
Ann Hynes Mizuho Securities USA Buy   Jun 01, '15   73.79  76.00  Jun 01, '16  4.58% 
Jeffrey Frelick Canaccord Genuity Buy   Apr 14, '15   72.83  85.00  Apr 14, '16  0.54% 
Jeffrey Frelick Canaccord Genuity Buy   Mar 03, '15   69.43  82.00  Mar 03, '16  -2.16% 
Isaac Ro Goldman Sachs Buy   Feb 26, '15   69.55    Feb 26, '16  -4.07% 
Robert Willoughby BofA Merrill Lynch Sell   Feb 23, '15   69.44    Feb 23, '16  3.95% 
Gary Lieberman Wells Fargo Securities, Llc Sell   Jan 30, '15   69.52    Jan 30, '16  5.54% 
Darren Lehrich Deutsche Bank Securities Buy   Nov 13, '14   62.42  75.00  Nov 13, '15  17.61% 
Anthony Vendetti Maxim Group Buy   Jul 25, '14   60.87  74.00  Jul 25, '15  20.54% 
Anthony Vendetti Maxim Group Buy   Jan 28, '14   52.24  68.00  Jan 28, '15  36.52% 
Isaac Ro Goldman Sachs Buy   Oct 02, '13   61.54  71.00  Oct 02, '14  -1.98% 
< previous12